Article
Oncogenic KRAS blockade therapy: renewed enthusiasm and persistent challenges.
Molecular cancer - 4 Oct 2021
Tang Daolin, Kroemer Guido, Kang Rui
Abstract excerpt
Across a broad range of human cancers, gain-of-function mutations in RAS genes (HRAS, NRAS, and KRAS) lead to constitutive activity of oncoproteins responsible for tumorigenesis and cancer progression. The targeting of RAS with drugs is challenging because RAS lacks classic and tractable drug binding sites. Over the past 30 years, this perception has led to the pursuit of indirect routes for targeting RAS...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.